canagliflozin

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: canagliflozin
• 英文别名: Canagliflozin alpha-Isomer Impurity；2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
• 化学式: C₂₄H₂₅FO₅S
• 分子量: 444.524
• InChiKey: XTNGUQKDFGDXSJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-allyloxy-2-{3-[5-(4-fluorophenyl)thiophen-2-ylmethyl]-4-methylphenyl}-6-hydroxymethyltetrahydropyran-3,4,5-triol 在 三乙基硅烷 、 三氟化硼 作用下， 以 二氯甲烷 、 乙腈 、 乙醚 为溶剂， 反应 2.5h， 生成 canagliflozin
  参考文献：
  名称：

  [EN] A NOVEL PIPECOLIC ACID CO-CRYSTAL OF CANAGLIFLOZIN AND PROCESS FOR THE PREPARATION THEREOF
  [FR] NOUVEAU CO-CRISTAL D'ACIDE PIPÉCOLIQUE DE CANAGLIFLOZINE ET SON PROCÉDÉ DE PRÉPARATION

  摘要：

  本发明公开了制备(2S,3R,4R,5S,6R)-2-{3-[5-[4-氟苯基)-噻吩-2-基甲基]-4-甲基苯基}-6-羟甲基-四氢吡喃-3,4,5-三醇及其吡啶氨酸共晶体的过程。本发明还公开了一种新的中间体，即乙酸4,5-二乙酰氧基-6-乙酰氧甲基-2-R1-2-{3-[5-(4-氟苯基)-噻吩-2-基甲基]-4-甲基苯基}-四氢吡喃-3-酯，其中，R1为烯丙基或丙-2-炔基，作为制备4,5-二乙酰氧基-6-乙酰氧甲基-2-R1-2-{3-[5-(4-氟苯基)-噻吩-2-基甲基]-4-甲基苯基}-四氢吡喃-3-酯的中间体，其中，R1为烯丙基或丙-2-炔基。

  公开号：

  WO2017060924A1

文献信息

• [EN] A NOVEL PROCESS FOR PREPARING (2S,3R,4R,5S,6R)-2-{3-[5-[4-FLUORO-PHENYL)- THIOPHEN-2-YLMETHYL]-4-METHYL-PHENYL}-6-HYDROXYMETHYL-TETRAHYDRO-PYRAN-3,4,5- TRIOL AND ITS STABLE AMORPHOUS HEMIHYDRATE FORM<br/>[FR] NOUVEAU PROCÉDÉ DE PRÉPARATION DE (2S,3R,4R,5S,6R)-2-{3-[5-[4-FLUORO-PHÉNYL)-THIOPHÉN-2-YLMÉTHYL]-4-MÉTHYL-PHÉNYL}-6-HYDROXYMÉTHYL-TÉTRAHYDRO-PYRAN-3,4,5-TRIOL ET DE SA FORME SEMI-HYDRATÉE AMORPHE STABLE
  申请人：HARMAN FINOCHEM LTD

  公开号：WO2016142950A1

  公开（公告）日：2016-09-15

  The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)-2-3-[5- [4-Fluoro-phenyl)-thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro- pyran-3,4,5-triol and its stable amorphous hemihydrate form.

  本发明揭示了制备(2S,3R,4R,5S,6R)-2-3-[5- [4-氟苯基)-噻吩-2-基甲基]-4-甲基苯基}-6-羟甲基四氢吡喃-3,4,5-三醇及其稳定非晶半水合物形式的过程。
• PHENYL C-GLUCOSIDE DERIVATIVE CONTAINING DEOXYGLUCOSE STRUCTURE, PREPARATION METHOD AND USES THEREOF
  申请人：Tianjin Institute Of Pharmaceutical Research

  公开号：EP3246324A2

  公开（公告）日：2017-11-22

  The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R1-R7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof.

  本发明提供了一种由式I表示的含有脱氧葡萄糖结构的苯基C-葡萄糖苷衍生物、其制备方法、包含其的药物组合物以及其在制备治疗糖尿病药物中的用途，其中取代基R1-R7如说明书中所定义。本发明还提供了一种合成含有脱氧葡萄糖结构的苯基 C-葡萄糖苷衍生物和中间产物的方法。该方法具有操作简单、成本低的优点，适合大规模工业化生产。本发明进一步提供了一种(1S)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-D-葡萄糖和 L-脯氨酸的共晶体及其制备方法和用途。
• Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
  申请人：Tianjin Institute of Pharmaceutical Research

  公开号：US10294259B2

  公开（公告）日：2019-05-21

  The present invention provides a phenyl C-glucoside derivative containing a deoxyglucose structure as represented by formula I, preparation method thereof, a pharmaceutical composition comprising the same, and uses thereof in the preparation of medicaments for treating diabetes, wherein substituents R1-R7 are as defined in the specification. The present invention also provides a method for synthesizing the phenyl C-glucoside derivative containing a deoxyglucose structure and an intermediate product. The method has advantages of being simple to manage and of low cost, which is suitable for large-scale industrial production. The present invention further provides a cocrystal of (1S)-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1,6-dideoxy-D-glucose and L-proline, and preparation method and uses thereof.

  本发明提供了一种由式I表示的含有脱氧葡萄糖结构的苯基C-葡萄糖苷衍生物、其制备方法、包含其的药物组合物以及其在制备治疗糖尿病药物中的用途，其中取代基R1-R7如说明书中所定义。本发明还提供了一种合成含有脱氧葡萄糖结构的苯基 C-葡萄糖苷衍生物和中间产物的方法。该方法具有操作简单、成本低的优点，适合大规模工业化生产。本发明进一步提供了一种(1S)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-D-葡萄糖和 L-脯氨酸的共晶体及其制备方法和用途。
• Agent for treating retinopathy
  申请人：CARNA HEALTH SUPPORT LTD.

  公开号：US10821126B2

  公开（公告）日：2020-11-03

  It is to provide an agent for treating and/or ameliorating retinopathy caused by glucose. It is an agent for treating retinopathy caused by glucose comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient, and is used at a normal dosage amount, or at a lower dosage whereby no lowering in blood sugar is observed.

  本发明旨在提供一种用于治疗和/或改善由葡萄糖引起的视网膜病变的制剂。它是一种治疗由葡萄糖引起的视网膜病变的药剂，其活性成分包括钠/葡萄糖共转运体2抑制剂（SGLT2抑制剂），以正常剂量使用，或以较低剂量使用，从而不降低血糖。
• Agent for treating retinal disease
  申请人：CARNA HEALTH SUPPORT LTD.

  公开号：US11382925B2

  公开（公告）日：2022-07-12

  Agent for treating retinal disease such as aged-related maculopathy comprising sodium/glucose cotransporter2 inhibitor (SGLT2 inhibitor) as an active ingredient.

  用于治疗视网膜疾病（如老年性黄斑病变）的制剂，其活性成分包括钠/葡萄糖共转运体 2 抑制剂（SGLT2 抑制剂）。